About Adaptive Phage Therapeutics
Adaptive Phage Therapeutics is a company based in Bethesda (United States) founded in 2016 was acquired by BiomX in March 2024. Adaptive Phage Therapeutics has raised $107.87 million across 11 funding rounds from investors including Amgen, Lilly and Bayer. The company has 78 employees. Adaptive Phage Therapeutics operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and BiomX, among others.
- Headquarter Bethesda, United States
- Employees 78
- SectorsHealthcare
- Email••••••••
- Website aphage.com/*
- Social X
- Acquired by BiomX (Mar 2024)
- Legal Name Adaptive Phage Therapeutics
Funding Insights of Adaptive Phage Therapeutics
Adaptive Phage Therapeutics has successfully raised a total of $107.87M across 11 strategic funding rounds. The most recent funding activity was a Series B round of $12 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $107.87M
- Total Rounds 11
- Last Round Series B — $12M
- First Round $765,000
(Apr 2017)
- Investors Count 11
Latest 10 of 11 funding rounds of Adaptive Phage Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | $12M | Series B | – | – | |
| Apr 2022 | $20M | Series B | – | Lilly, Amgen | |
| Sep 2021 | $8M | Grant | – | – | |
| May 2021 | $61M | Series B | – | Deerfield | |
| Aug 2020 | $7M | Series B | – | Mayo Clinic Business Accelerator | – |
| Jun 2020 | $3.35M | Debt – Conventional | – | – | – |
| Dec 2019 | – | Series A | – | Hackensack Meridian Health | – |
| Oct 2019 | $7M | Series A | – | Alexandria | – |
| Feb 2018 | $100,000 | Seed | – | – | |
| Jan 2018 | $2.35M | Debt – Conventional | – | – | – |
12 investors in total: 12 institutional.
Investors in Adaptive Phage Therapeutics
Adaptive Phage Therapeutics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, Lilly and Bayer.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in antimicrobial resistance treatment development. | – | amractionfund.com | - | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | – | deerfield.com | New York, United States | |
Healthcare startups are accelerated by Mayo Clinic Business Accelerator. | – | mcbusaccel.com | Rochester, United States | |
Venture capital fund and startup accelerator programs focused on seed and early stage companies | 1998 | tedcomd.com | Columbia, United States | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | amgen.com | Thousand Oaks, United States | |
Life science solutions for healthcare and agriculture are delivered. | 1863 | bayer.com | Leverkusen, Germany | |
- | – | defence.gov | - | |
General medical clinics are operated throughout the United States. | 1864 | mayoclinic.org | United States | |
Standalone multispecialty hospitals are operated across the United States. | 2016 | hackensackmeridianhealth.org | Edison, United States |
Investor details for Adaptive Phage Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Adaptive Phage Therapeutics
12 people are tracked at Adaptive Phage Therapeutics (4 in leadership, 5 in board & advisors, 3 in team); the tracked headcount is 78.
| Name | Role | Group |
|---|---|---|
Greg Merril | – | Leadership |
Rob Casper | Vice President Clinical Operations | Leadership |
Carl R. Merril | Chief Scientific Officer | Leadership |
Mike Sowers | Director, Quality | Leadership |
Jonathan Leff | Director | Board & advisors |
Evan Loh | Director | Board & advisors |
Martin Heidecker | Director | Board & advisors |
Raymond D. Martz | Director | Board & advisors |
Jesse Goodman | Director | Board & advisors |
Dale Eadie | Clinical Research Program Manager | Team |
Emae Lee-Voritskul, CPA | Corporate Controller | Team |
Siblian Boston | Clinical Trial Manager | Team |
Complete people profiles for Adaptive Phage Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Adaptive Phage Therapeutics
4 dated milestones of Adaptive Phage Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Adaptive Phage Therapeutics is founded.
- Funding First funding round of $765K.
- Funding Latest funding round, Series B, of $12.0M.
- Exit Acquired by BiomX.
Competitors of Adaptive Phage Therapeutics
Adaptive Phage Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and BiomX, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| nabriva.com | 2006 | Vienna, Austria | $193.08M | – | Pleuromutilin antibiotics are developed for MDR infections. | |
| melinta.com | 2000 | Morristown, United States | $186M | 290 | Developer of bacterial ribosome-targeting drugs for MDR infections | |
| iterumtx.com | 2015 | Dublin, Ireland | $78.1M | – | Developer of antibiotics for MDR infections | |
| biomx.com | 2015 | Ness Ziona, Israel | $56M | – | Microbiome therapeutics are developed for dysbiosis-linked diseases. | |
| paratekpharma.com | 1996 | Boston, United States | $96.48M | 205 | Therapeutics for antimicrobial resistant infections are developed. | |
| locus-bio.com | 2015 | Raleigh, United States | $67.33M | 74 | Developer of therapeutics for infectious disease and inflammatory indications | |
| vedantabio.com | 2010 | Cambridge, United States | $350.49M | 71 | Therapeutics for infectious and autoimmune diseases are developed. | |
| allecra.com | 2013 | – | $44.44M | – | Antibiotics for multi-drug-resistant bacterial infections are developed. |
Detailed competitors of Adaptive Phage Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adaptive Phage Therapeutics
Complete news archive for Adaptive Phage Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Adaptive Phage Therapeutics
10 companies that operate in the same segment as Adaptive Phage Therapeutics (Microbiome Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Biosolutions and enzymes are developed for biotechnology applications across industries. | 2000 | Bags Sword, Denmark | – | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Gut microbiome insights, analytics, tests, and therapeutics are provided. | 2019 | Singapore, Singapore | USD 10.5 M | USD 1.37 M | – | |
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | – | 12 | |
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Microbiome-based therapeutics for gut diseases are developed. | 2017 | Edinburgh, Scotland, United Kingdom | USD 72.96 M | – | 65 | |
The gut-brain axis is explored for therapeutic and nutritional innovations. | 2014 | New York, New York, United States | USD 479 M | – | 84 | |
Microbiome therapeutics are developed to address diverse diseases. | 2010 | Cambridge, Massachusetts, United States | USD 257.13 M | USD 789 K | 103 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Adaptive Phage Therapeutics
Adaptive Phage Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Adaptive Phage Therapeutics is headquartered in Bethesda, United States. It is registered at Bethesda, Maryland, United States.
Adaptive Phage Therapeutics is a funded company, having raised a total of $107.87M across 11 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $2.35M, raised on Apr 2017.
Adaptive Phage Therapeutics has 78 employees.
Adaptive Phage Therapeutics was founded in 2016 and is based in Bethesda, United States. Operations focus on the biotechnology sector, where therapies for multi-drug resistant bacterial infections are provided through PhageBanking, a collection of targeted bacteriophages. A rapid matching system pairs phages with patient-specific infections. Success in a first-in-human case involving Acinetobacter baumannii has been achieved, supporting patient survival.
Adaptive Phage Therapeutics's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Adaptive Phage Therapeutics has 12 investors. Key investors include Amgen, Lilly, Bayer, ARE, and Mayo Clinic.
Adaptive Phage Therapeutics operates through Adaptive Phage Therapeutics.
Yes. Adaptive Phage Therapeutics was acquired by BiomX in March 2024.